Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sarcoma

1783 - Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors (GIST) treated with imatinib (484O)

Date

18 Nov 2017

Session

Sarcoma

Presenters

Piotr Rutkowski

Citation

Annals of Oncology (2017) 28 (suppl_10): x149-x152. 10.1093/annonc/mdx675

Authors

P. Rutkowski1, P. Teterycz1, A. Klimczak1, E. Bylina2, K. Szamotulska3, I. Lugowska1

Author affiliations

  • 1 Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, 02781 - Warsaw/PL
  • 2 Clinical Trial Unit, Maria Sklodowska-Curie Institute - Oncology Center, 02781 - Warsaw/PL
  • 3 Biostatistics, Institute of Mother and Child, Warsaw/PL
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1783

Background

Neutrophil-to-lymphocyte ratio (NLR) was shown to be prognostic in several solid malignancies. There are limited data about predictive/prognostic value of NLR during targeted therapy of patients with advanced gastrointestinal stromal tumors (GIST). The aim of the study was to asses a clinical value of this ratio in patients with advanced GIST.

Methods

Between 2001 and 2016, 385 patients with metastatic/unresectable GIST treated initially with imatinib were included to the analysis. In all patients the NLR was assessed at the baseline, after 3 months of treatment and upon disease progression (or last observation). The cut off for NLR was set at 2.7. Kaplan-Meier survival probability estimation with in log-rank test, and Cox's proportional hazards model were used for analysis.

Results

Median Progression-Free Survival (PFS) on imatinib treatment was 44.8 months, 5-year rate 43%; median Disease Specific Survival (DSS) – 87.2 months, 10-year rate 36.3%. NLR >2.7 at baseline was significantly associated with poorer OS and DSS: median DSS was 89.3 months (95%CI 80.2-115) for NLR ratio ≤2.7 vs. 59.4 months (95%CI 48.6-82) for NLR >2.7 (p 

Conclusions

Our results demonstrate the usefulness of NLR as a prognostic and predictive marker as well as marker for treatment monitoring in patients with advanced GIST treated with imatinib.

Clinical trial identification

Legal entity responsible for the study

Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland

Funding

None

Disclosure

P. Rutkowski: I have received honoraria for lectures from Novartis, Roche, Pfizer, BMS, MSD and served as a member of Advisory Board for Novartis, Merck, Amgen, Blueprint, Roche, BMs and MSD.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.